Sage Therapeutics Inc (SAGE) reports significant prescription growth for ZURZUVAE, despite a net loss and strategic ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago. These ...

Investment losses are painful at any point, but losing stocks are even harder to stomach when the market is in the midst of a ...